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II.

Abstract

Background: Dyslipidemia is a leading cause of death globally. In the United States, patient
compliance with medical advice for the treatment of dyslipidemia is overlooked, exacerbating
health complications for the patient. The lack of patient engagement with care has been traced
back to a lack of provider knowledge and poor counseling of patients to foster participation in
their care.
Aim: This quality improvement project aimed to educate providers about the proper
management of dyslipidemia to improve their knowledge of the topic.
Methodology: A pre-/post-educational intervention design was used to evaluate the knowledge
of healthcare providers working in convenient care clinics. Advanced Practice Providers (APPs)
working in this setting voluntarily agreed to have their knowledge of the management of
dyslipidemia assessed, to participate in an educational program, and to have their knowledge of
the topic measured following educational intervention.
Results: n = 24 providers agreed to participate in the project. Of these a majority were women (n
= 23, 96%) and of Latino race (n = 11, 46%). Mean knowledge scores were tabulated before (M
= 5.5, SD = 3.48) and after (M = 13.5, SD = 4.41) the educational program. The results indicated
an increase in knowledge that was found to be statistically significant, t(23) = 5.33, p <.001.
Implications: The results of this quality improvement project support the use of provider
education to increase knowledge of proper management of dyslipidemia. Over time, increased
provider knowledge should correlate with changes in practice that improve patient engagement
with their care and outcomes for patient’s health.
Keywords: dyslipidemia, healthcare provider, education, convenient care clinic
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IV.

Introduction-Problem Statement/Significance.

Dyslipidemia has emerged as a global public health issue, ranking second only to
ischemic heart disease and stroke as the leading causes of death. Dyslipidemia is a primary cause
of coronary artery disease. When compared to people with normal lipid levels, people with
dyslipidemia have twice the chance of getting cardiovascular disease (CVD). Dyslipidemiarelated complications, such as CVD, are common causes of death. Additionally, high levels of
lipids raise the risk of atherosclerosis, which is a major risk factor for stroke, coronary heart
disease, and peripheral vascular disease.
In the United States a medical research study accomplished by the Multi-Ethnic Study of
Atherosclerosis (MESA) found that about a third of the patients had elevated low-density
lipoprotein (LDL-C), while two-thirds had increased triglycerides (hypertriglyceridemia). Only
41% of individuals taking medication met the suggested LDL-C target of less than 77mg/dL
(Borrayo-Sánchez, 2021).
The magnitude of this health problem is demonstrated by its prevalence in numerous
countries. In Canada, 45 percent of persons aged 18 to 79 had no idea they had dyslipidemia, and
only 19 percent had levels below the recommended range. Hypercholesterolemia affected 23.3
percent of people in France, even though only 7.2 percent received treatment. Along with
patients taking secondary preventive medication, only 29.7 percent saw a reduction in lipid
levels in a period of six-month treatment. In Mexico, according to a recent survey, the country's
population has low levels of HDL-C, high LDL-C levels, and hypertriglyceridemia was present
in half of the respondents. More than two-thirds of a middle-class urban population sample
exhibited hypoalphalipoproteinemia, with one-third having cholesterol levels greater than 240
mg/dL and 36% having LDL-C levels greater than 130 mg/dL (Borrayo-Sánchez, 2021).
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Sudden cardiac death (SCD) and acute myocardial infarction (AMI) happened because of
atherosclerotic coronary artery disease (ASCAD) mainly to patients who have hereditary
hyperlipidemia causing coronary plaque disturbance and acute coronary thrombosis. Because
plaque builds up in the arteries, high LDL-C raises the risk of atherosclerotic coronary artery
disease (Thompson et al., 2015). Untreated dyslipidemia raises the expense of healthcare for
individuals in the long perspective. In 2021, direct costs as a percentage of total healthcare
spending on all populations ranged from $17 to $259 million (Ferrara et al., 2021). As a result,
treating the disease helps the country achieve its aim of providing safe, low-cost healthcare.
The delivery of high-quality and consistent services is a big hurdle in the healthcare
system. Nurses comprise the largest group of healthcare providers (Debono et al., 2013). They
have more contact with patients than any other healthcare professional. As a result, Advanced
Practice Providers (APPs), are expected to keep updated with modern nursing practices that
involve integrating evidence-based practices, and aware of most current theoretical and practical
knowledge. Inadequate understanding in dyslipidemia management impedes proper treatment of
the condition and increase patients’ risks for developing chronic conditions such as stroke and
coronary heart disease (CHD).
Similarly, Zhang et al. described that hyperlipidemia is a substantial risk factor for
coronary artery disease (CAD) (Zhang et al., 2017). Lack of sufficient knowledge and skills
among health care providers treating patients with dyslipidemia has been proven to raise patients'
risks of acquiring chronic illnesses like coronary heart disease (CHD), which is a major cause of
morbidity and death in the United States (Khammarnia et al., 2015). Abnormal cholesterol levels
have been associated to a variety of cardiovascular problems. Stroke and hypertension, for
example, are linked to high triglyceride (TG), total cholesterol (TC), and low-density lipoprotein
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cholesterol (LDC-C) levels. There are modifiable risk factors (RFs) such as smoking,
hypertension, obesity, dyslipidemia, and diabetes mellitus that play a major role in the
development of CHD (Bucholz et al., 2018).
LDL-C is a critical focus of inquiry among lipid abnormalities since multiple studies
have linked elevated serum LDL-C with increased cardiovascular disease morbidity and death
(Kayani & Ballantyne, 2018; Yandrapalli et al., 2019). LDL-C levels above 190 mg/dL are
indicative of familial hypercholesterolemia (Bulchoz et al., 2018). Statins are considered the
first-line therapy to treat elevated cholesterol disorders because of their documented efficacy.
Nonetheless, the most recent data indicates that their prescription rates in young adults
with severe dyslipidemia are moderate (Al-Kindi et al., 2017). It is critical to diagnose and
overcome gaps in the diagnosis and treatment of severe dyslipidemia, especially with the
introduction of novel agents such proprotein convertase subtilisin/Kexin type 9 (PCSK9) (Del
Pinto et al., 2019).
There are significant gaps in management of dyslipidemia, as Barter et al. point out, that
obstruct the management of dyslipidemia in people at high risk of atherosclerotic cardiovascular
disease (ASCVD) (Barter et al., 2020). In the therapy of dyslipidemia, there are various areas of
uncertainty. As an example, Barter et al. found out that the target low-density lipoprotein
cholesterol (LDL-C) level recommended by physicians varied across countries participant:
Colombia (80 mg/dL), the Philippines (85 mg/dL), Germany (86 mg/dL), and Japan (96 mg/dL),
as well as discrepancies on the LDL-C target levels in individuals with peripheral artery disease,
diabetes, or chronic kidney disease (CKD) or coronary heart disease, according to the doctors.
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Another source of inconsistency is the pharmacotherapeutic alternatives for treating
hypertriglyceridemia in patients with chronic kidney disease (CKD). While the four countries'
pharmacotherapeutic choices for hypertriglyceridemia in chronic kidney disease (CKD) were
similar (statins, fibrates, and omega-3 fatty acids), 30 percent of German doctors believed that
the most recommended treatment for CKD was lifestyle change modifications alone. Physicians
also expressed divergent views on the safety of low LDL-C levels, with the majority expressing
concern about the risk of hemorrhagic stroke (Barter et al., 2020). Finally, doctors in the four
nations raised concern about statins' negative effects on cognitive, renal, and hepatic function.
Although the findings of Barter et al. s’ study cannot be applied to all physicians and healthcare
providers worldwide, they do provide important insight into the knowledge gaps in the
management of dyslipidemia.
V.

Summary of the literature review/Evidence related to the clinical question.

Managing dyslipidemia and hypercholesterolemia necessitates overcoming obstacles that
frequently result in gaps in the practices of healthcare professionals. The primary goal of this
literature review is to gather crucial information on these two medical diseases as well as the
challenges they face in treatment. Heart disease is the leading cause of death in the United States,
affecting men, women, and individuals of all races and ethnicities. Every year, around 659,000
people in the United States die from heart disease, accounting for one out of every four deaths
(CDC, 2022). The United States spent $363 billion on heart disease between 2016 and 2017.
Medical services, drugs, and lost production due to mortality are all included. Coronary heart
disease, the most common type of heart disease, claimed the lives of 360,900 persons in 2019.
Annually, about 805,000 people in the United States suffer a heart attack. A first heart attack
affects 605,000 people, with 200,000 incidents involving persons who have already had a heart
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attack. Medical disorders such as high blood pressure, high cholesterol, and smoking aggravate
heart disease.
Cardiovascular disease (CVD) is the most common cause of hospitalization in the United
States, accounting for 973,000 admissions for heart attacks alone. The annual rate of new
myocardial infarction is estimated to be around 565,000. (Srikanth & Deedwania, 2016). Every
year, over 500,000 people are estimated to experience a heart attack for the first time (Srikanth &
Deedwania, 2016). In the United States, most dyslipidemias are hyperlipidemias (i.e., high lipid
levels in the blood). The imbalance of cholesterol levels in the blood, including high-density
lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), is known as
hyperlipidemia. This disorder is frequently linked to patient lifestyle and dietary habits. The
amount of cholesterol in blood is measured by HDL-C and LDL-C levels, and an imbalance can
increase the risk of cardiovascular events like stroke and myocardial infarction. LDC-C promotes
plaque accumulation in the arteries, which is associated to a higher risk of stroke and coronary
heart disease (Srikanth & Deedwania, 2016). The HDL-C works to lower cholesterol levels in
the body, decreasing the risk of atherosclerotic cardiovascular disease (ASCD).
Atherosclerosis on the other hand, is a chronic inflammatory process that targets medium
and large sized arteries. However, the condition is rapidly accelerated by a variety of genetic and
environmental factors. The pathologic processes underlying the condition can be categorized into
three progressive stages: fatty streak formation, plaque formation, and plaque disruption. Some
of the biomarkers of the condition are C-reactive protein (CRP), hyperhomocysteinemia, and
lipoprotein (Lilly, 2021). As a result, the biomarkers are regarded to as modifiable risk factors as
they have a beneficial effect on the primary and secondary prevention of the diseases. A
biomarker such as the lipoprotein relates to a variety of functions such as inhibition of
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fibrinolysis by preventing the transformation of plasminogen to plasmin, enhanced capacity to
traverse the arterial endothelium. and low affinity for the LDL-receptor.
According to Rodriguez et al., about 53 percent (100 million) of adults in the United
States have elevated LDL-C values. Additionally, more than 31 million adults in the country
have cholesterol levels of more than 240 mg/dL, putting them at a high risk of developing
ASCVD (Rodriguez et al., 2014). However, only just about half of those with high LDL-C levels
receive medication to reduce their levels. Furthermore, only about 35% of individuals who
receive treatment obtain satisfactory therapy. (Srikanth & Deedwania, 2016).
Dyslipidemia is linked to a variety of risk factors. Obesity, smoking, sedentary lifestyle,
and unhealthy dietary habits consuming foods dense in trans, or saturated fats are all modifiable
risk factors. Hypothyroidism, high blood pressure, type 2 diabetes, chronic renal disease, and
biliary obstruction are all secondary causes of elevated LDL-C. (Rodriguez et al., 2014). Some
medications that can raise LDL-C levels include but not limited to glucocorticoids, cyclosporine,
and diuretics. While gender and ethnicity have been demonstrated to play a role in
hyperlipidemia development, the data on these factors has been mixed.
Genetics also play a critical role in developing increased cholesterol in the form of
familial hypercholesterolemia (FH). FH is an autosomal trait characterized by increased LDL-C
and total cholesterol levels from premature ASCVD and birth. It results from genetic mutations
in the LDL receptor leading to decreased LDL metabolism (Rodriguez et al., 2014). Also,
genetic mutations can occur in the apolipoprotein (apo) B gene, which decreases the binding of
LDL receptors to the LDLR.
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Lipids play an important role in living organisms as they act as a source of energy. In the
western diets, lipid provide 30% to 40% of calories. In the human body, the small intestines are
the main site of lipid transformation and absorption. Lipid transformation is aided by an enzyme
known as chylomicrons which is also secreted in the small intestines. Chylomicrons are large
lipoproteins very rich in lipids and are composed mainly of triglycerides. However, cholesterol
levels may harden inside the body resulting from low-density lipoproteins (LDL) (Lilly, 2021).
Increased level of LDL result from a deficiency of estrogens and thyroid hormones or genetic
mutations of either the LDL receptor or Apo B-100.
Lipoproteins may take another maybe also found in the form of High-Density Proteins
(HDLs) which have a protein concentration of 33% and help remove cholesterol from the
periphery and transports it to the liver. The two most important subclasses of HDL express either
Apo A-II alone or both Apo A-I and A-II. Researchers have suggested that high levels of HDL
have a protective effect on the development of atherosclerosis (Lilly, 2021). Therefore, patients
are advised to increase their HDL levels. Primary Hyperlipidemia results from single or multiple
genetic mutations in the endogenous lipid pathways. As the disease progresses, some of the signs
and symptoms that develop include obesity, lipemic plasma, and severe hypertriglyceridemia. In
the United States, the Polygenic hypercholesterolemia is the most common form of
hyperlipidemia with a prevalence of 25%.
Secondary hyperlipidemias are associated with primary underlying conditions such as
obesity, diabetes, alcohol abuse, and hypothyroidism. along with polygenic
hypercholesterolemia, atherogenic dyslipidemia is one of the most common forms of
hyperlipemia’s. Patients with such diseases are treated with lifestyles changes aimed at weight
reductions (Lilly, 2021). It can also be associated to medications including the use of estrogen
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therapy, atypical antipsychotics, corticosteroids, and thiazides. Secondary hyperlipidemias with
elevated cholesterol are the main dyslipidemia in patients with chronic renal failure and
hypothyroidism.
Controlling dyslipidemia is critical for reducing its detrimental health consequences.
Disproportionate triglycerides (TG), total cholesterol (TC), and LDL, as well as low high-density
lipoprotein (HDL), all contribute to atherosclerosis. As a result of these imbalances, it leads to
higher risk of atherosclerosis among patients with nephrotic syndrome (NS), which promotes the
development of cardiovascular diseases (Tao et al., 2020). When patients with dyslipidemia do
not take preventive measures seriously, the excessive cholesterol gradually deposit in the arterial
intima promoting connective tissue hyperplasia causing arterial wall enharden leading to
atherosclerotic plaque formation. As a result, Tao et al. (2020) assert that they may undergo
plaque production enhancement, raising their risk of strokes, heart disease, and coronary artery
disease (CAD).
According to Tao et al. (2020), chronic dyslipidemia can lead to thromboembolism,
which affects 25 and 37 percent of adolescents and adults, respectively. As a result, when faced
with the prospect of developing peripheral artery disease (PAD), one could claim that engaging
in physical exercise is critical in reducing the illness's negative implications. Unfortunately,
uncontrolled dyslipidemia can lead to additional diseases and mortality in the affected
individuals.
To manage dyslipidemia, two main practices are used: lifestyle modification and
medication therapy. These methods aid in lowering the risk of coronary heart disease (Jang et al.,
2021). Cholesterol levels that are too high are a common modifiable risk factor. According to
studies, lowering total cholesterol in the blood is connected to a lower risk of coronary heart
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disease (CHD) (Jang et al., 2021). In the last two decades, LDL-C has been the principal target
of lipid intervention in CHD prevention (Jang et al., 2021). The development of powerful
medicines for lowering this lipid sub-fraction has been a focus of efforts to improve cholesterol
controlling medication. Successful lipid control usually requires instruction by a dietitian or
other knowledgeable healthcare professional. Recent genetic and molecular research advances,
on the other hand, have improved our understanding of the complicated lipid metabolic
processes.
After decades of recommending diets that limit cholesterol, saturated fat, and total fat
intake, the American Heart Association (AHA) has lately established a nutritional strategy that
focuses on the overall healthy eating pattern (Jang et al., 2021). The 2018 AHA/ACC guidelines
use percentage reduction to estimate the efficacy of statin therapy with the goal being 50% or
more. Additional guidelines have suggested a dietary pattern that emphasizes the intake of fruits
and vegetables, reduce calories from trans-fat, allow for no more that 5% to 6% of calories from
saturated fats and include low-fat dairy products (Virani et al., 2020).
The dietary recommendation includes targets for a healthy eating pattern, a healthy blood
pressure, a healthy lipoprotein and cholesterol lipoprotein profile, and a healthy body weight
(Jang et al., 2021). The goal of optimal body weight guidelines is to match energy intake to
energy needs while adjusting achieve a healthy weight. Controlling foods high in cholesterol and
saturated fat and replacing them with grains and unsaturated fats from nuts, legumes, seafood,
and vegetables are some of the recommendations for achieving a healthy body weight.
According to the AHA/ACC, for patients 75 years of age or younger with clinical ASCVD on
high-intensity therapy, the target percentage LDL reduction should be 50% or greater. The
guidelines recommend keeping a healthy body weight, reducing alcohol and salt intake, and
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eating a diet rich in vegetables, fruits, and nonfat or low-fat dietary products to achieve optimal
blood pressure (Virani et al., 2020). Recent secondary dyslipidemia preventative dietary trials
have found that diets low in saturated and total fats and high in plant or fish omega-3 fatty acids
reduce the occurrence of secondary dyslipidemia (Jang et al., 2021).
Controlling risk factors of dyslipidemia and lowering mortality and morbidity rates
related to this health problem requires careful management. Dyslipidemia management was
investigated by Arnold and Buelt (2021) to improve cardiovascular prevention. The researchers
emphasized the importance of making appropriate treatment decisions based on 10-year risk
calculators since they correspond to the individuals that frequently benefit from clinical trials.
Similar idea is shared by O'Malley et al. (2020). LDL-C levels have consistently been
linked to cardiovascular morbidity and mortality in observational studies, focuses on the
management of dyslipidemia to lower the risk of cardiovascular disease (CVD) (O’Malley et al.,
2020). According to O’Malley et al., the use of target medication doses consistent with moderate
stain doses, as evidenced in some clinical trials, it can manage the condition (O'Malley et al.,
2020. While neither study found therapy to be successful, the authors indicated that a more
comprehensive strategy could help alleviate the effects of dyslipidemia.
When it comes to managing dyslipidemia, another option is to change the diet. A
proposed one, according to Arnold and Buelt (2021), is the Mediterranean diet that lowers
incidence of cardiovascular events, stroke, type 2 diabetes, and all-cause mortality. The diet, as
stated by O'Malley et al. (2020), is well appropriate to high-risk patients. The Mediterranean diet
include high unsaturated–saturated fat ratio, high proportion of caloric intake from plant-based
foods (fruits, vegetables, nuts, legumes, and grains), moderate consumption of fish and low-fat
dairy products, and low intake of lean meat and red wine, according to O'Malley et al. (2020).
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While the researchers advise patients to examine other diets with similar components, they
emphasize that the Mediterranean diet is the only one that has been studied in a randomized
controlled trial (RCT) with a primary focus on CVD outcomes.
The explanation includes the use of omega-3 fatty acids, which both Arnold and Buelt
(2021) and O'Malley et al. (2020) agree are effective dietary supplements for lowering CVD
risks. Despite significant studies on omega-3 acid supplementation, the researchers claim that
there is no evidence that omega-3 supplements reduce cardiovascular risks. Moreover, while
there is inadequate evidence to recommend specific meals, the existing research suggests that
fiber, ginger, green tea, garlic, and red yeast are beneficial for dyslipidemia (Arnold & Buelt,
2021; O'Malley et al., 2020). Consequently, even though these sources promote dieting, the
researchers found that, aside from the Mediterranean diet, it is still unclear if omega-3 fatty acids
can aid in the management of the illness. Omega-3 fatty acids are abundant in fatty fish, walnuts,
canola, and vegetable oils. However, Omega-3 polyunsaturated fatty acids are considered
essential fatty acids because humans, as well as mammals, are unable to synthesize these
compounds efficiently.
Physical activity is another management strategy. According to Arnold and Buelt (2021),
it is a tried-and-true method for reducing cardiovascular events. Sedentary persons, they say, are
the ones who profit the most from the process since they don't do enough aerobic physical
activity. According to O'Malley et al. (2020), the Physical Activity Guidelines for Americans
recommend 150 minutes of moderate-intensity or 75 minutes of intense physical activity each
week (O'Malley et al., 2020). Arnold and Buelt (2021) discovered that participating in the
method for eight weeks after revascularization or a cardiovascular event can avoid myocardial
infarction and death for more than ten years. While insisting on the importance of the process,
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O'Malley et al. (2020) contend that regular physical activity of any time and intensity is most
consistent with the present research. While there is no consensus on the appropriate level of
physical activity, it is obvious from the sources that implementing the strategy can help minimize
the risk of dyslipidemia.
Statin medication are an important part of managing dyslipidemia, according to experts.
In China, Chen et al. (2020) investigated condition management for the prevention of ischemic
stroke recurrence. The researchers discovered that a study by the Stroke Prevention by
Aggressive Reduction in Cholesterol Levels (SPARCL) had proven that statin lipid-lowering
medication may reduce dyslipidemia in their meta-analysis methodology. The researchers
confirmed that statin medication could prevent ischemic stroke with an odds ratio (OR) of 0.51,
with a 95 percent confidence interval (CI) of 0.36-0.72, despite not prescribing it for older
persons (Chen et al., 2020). Types of statins include simvastatin, lovastatin, pravastatin,
fluvastatin, and pitavastatin. However, simvastatin has proven to be the most effective statin.
Moderate-dose statin medication is also recommended as a primary preventative strategy by
O'Malley et al. (2020). As stated, the percentage reduction in LDL levels is used to estimate the
efficacy of statin therapy with a goal of 50 % reduction. In addition to the lipid-lowering actions
of statins, studies suggest that there are pleiotropic effects such as modulation of endothelial
function, decrease in vascular inflammation, neuroprotection, and immunomodulation of
inhibition. Clinical trials suggest that moderate-dose statin medication for five years can reduce
CVD risk by 20 to 30 percent for patients with a 10-year risk greater than 12 percent, according
to the researchers' systematic review (O'Malley et al., 2020). Even though certain experts have
advocated for the use of non-statin medicines, the latter claims that no one clinical research has
proven that they can lower cardiovascular mortality. Administration of a statin with a bile acid-
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binding resin produces 20% to 30% greater reductions in LDL than statin monotherapy. With
this evidence, it is reasonable to believe that statin medication can help manage dyslipidemia.
O'Malley et al. (2020) assert in their comprehensive review that there is significant
evidence that high-dose statin medication reduces cardiovascular morbidity but not mortality
when compared to low- or moderate-dose statin therapy. This evidence comes primarily from
higher-risk secondary prevention populations, such as those who have had a recent MI or acute
coronary syndrome in the previous 12 months, recurrent acute coronary syndrome, MI, or stroke,
or established CVD with additional major risk factors like current tobacco use, diabetes,
peripheral artery disease, or previous coronary artery bypass graft surgery or percutaneous
coronary intervention (O'Malley et al., 2020). With such occurrences, the researchers looked at
other evidence and discovered that proprotein convertase subtilisin/Kexin type 9 (PCSK9) and
ezetimibe inhibitors for higher-risk individuals can help improve their position by lowering
cardiovascular morbidity (O'Malley et al., 2020). The researchers, however, criticized PCSK9
inhibitors for their unknown long-term safety and expensive cost, concluding that they should
only be used as a last resort. Because of the information gathered from the three sources while
there are several approaches to managing dyslipidemia, none of them can entirely produce better
results than the others. Under lipid-lowering method, Nicotine Acid Derivatives, Niacin, also
known as nicotinic acid or Vitamin B3 acts as an important cofactor in intermediary metabolism.
It inhibits lipoproteins lipase and prevents triglyceride release from chylomicrons. Niacin has a
low cost, a long history of clinical trials, and extensive use as a safe lipid-lowering drug,
supported by evidence that is effective in the prevention of ASCVD. Health professionals
questioned the processes' efficacy and their ability to change patients' situations because of their
low acceptance.
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There are gaps in dyslipidemia management in different nations as well. For example,
Barter et al. (2020) investigated discrepancies in practice and beliefs in the management of the
illness in four countries: the Philippines, Germany, Colombia, and Japan. Their systematic study,
which mostly used data from a web-based physician survey, discovered that there is still debate
over LDL-C targets, statins, and the safety of low LDL-C levels. When discussing the latter,
Barter et al. (2020) stated that participant physicians from the four countries agreed that taking
statins could raise a person's risk of hemorrhagic stroke by impairing renal and cognitive
function. Furthermore, the evidence revealed a lack of agreement on the perceived need to lower
the stain dose in patients with chronic kidney disease (CKD), the necessity for varied LDL-C
target levels based on CKD stage, and the clinical benefits of treating hypertriglyceridemia in
CKD patients (Barter et al., 2020). Likewise, they were unable to demonstrate the efficacy of
PCSK9 inhibitors in the treatment of dyslipidemia, indicating that further study and education is
required to develop the best management strategy for the disease.
There are unique barriers that prevent the processes from being achieved. Patients'
limited adherence to existing drugs and other therapeutic options is a major stumbling block.
Wändell et al. (2018) highlighted possible facilitators and particular impediments to
cardiometabolic disease (CMD) selective prevention in primary care for healthcare workers.
They used a systematic review approach and discovered that nine of the 28 trials showed
minimal or no patient adherence to the prescribed practices. Alefishat et al. (2021) investigated
factors associated with medication non-adherence in individuals with dyslipidemia. Many of the
study participants stated that their lack of interest in cholesterol-lowering medications stemmed
from the disruptions they made in their life, according to the researchers. Others expressed
concern about becoming too reliant on the medications to the point where they couldn't function
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without them (Alefishat et al., 2021). As a result of these claims, many patients have reduced
their desire to follow the established rules.
One of the biggest obstacles to managing pain control for hospitalized patients is nurses'
attitudes and expertise (Germossa et al., 2018). A technique for enhancing nurses' attitudes and
understanding about pain treatment was established to be an educational program. Total of 111
nurses from the Jimma University Medical Center participated in a quasi-experimental study
where they underwent to two days of rigorous pain management training, followed by a
subsequent training session one month afterwards, and results were statistically significant in a
substantial pain control management (Germossa et al., 2018).
Wändell et al. (2018) criticize health providers for dismissing accessible drugs as
ineffective for patients. Others believe the methods are unsuccessful, owing to lower levels of
adherence among the patients they see in medical institutions. Wändell et al. (2018) discovered
that employees frequently find problems when counseling patients regarding alternative lifestyles
in their study due to lack of counseling skills. They claimed that many people questioned their
ability to persuade others to change their behaviors. Health professionals questioned the
processes' efficacy and their ability to change patients' situations because of their low
acceptance. Additionally, certain employees have shown biases, which has dissuaded people
from seeking help (Wändell et al., 2018). Medical professionals have impeded the
implementation of critical guidelines to control the disease because of these incidents.
The knowledge of health care providers is also critical for the acceptance of guidelines.
Unfortunately, according to Wändell et al. (2018), five of their research found that professionals'
lack of basic knowledge often leads to them failing to utilize existing strategies. They attribute
the prevalence to the group's lack of effectively communicate risk and lifestyle information due
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to insufficient education, training, or skills (Wändell et al., 2018). For example, the authors point
to a lack of knowledge as a major factor in unsuccessful counseling, claiming that it reduces
patients' motivation to cooperate during sessions. Besides, achieving an effective process
necessitates medical experts motivating and encouraging patients to embrace accessible
strategies such as offer a great deal in the way of lifestyle counselling. Wändell et al. (2018)
point out that their participants have little motivation, which limits their capacity to follow the
advised technique.
Ab et al. (2009) carried out a study investigating the factors underlying general
practitioners’ decisions not to prescribe lipid-lowering drugs to type 2 diabetes patients. The
qualitative study involved semi-interviews using real cases to explore reasons for general
practitioners not prescribing statins in most patients with diabetes (Ab et al., 2009). The study
came up with reasons divided into physician and patient-attributed factors. According to the
general practitioners, some patients do not comply with the prescribed medications, while others
refuse to take lipid-lowering medications. Besides, the general practitioners perceived
reservations for prescribing medications lipid-lowering levels. General practitioners sometimes
suspend treatment because of other priorities (Ab et al., 2009). Barriers mentioned by general
practitioners seem to have valid reasons indicating that non-compliance to prescribed
medications can be rational. Conversely, the quality of treatment can be improved by addressing
issues such as inadequate knowledge in managing dyslipidemia and lack of motivation of both
general practitioners and the patient (Ab et al., 2009).
As a result of these challenges, the researchers concluded that overcoming dyslipidemia
and hypercholesterolemia is typically difficult due to patients' lack of adherence, medical
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personnel's negative attitudes and biases, and healthcare providers' insufficient awareness of the
appropriate standards.
Since dyslipidemia is one of the major causes of mortality in the country, an evidencebased educational program to bridge knowledge gaps presents an opportunity to improve patient
outcomes. Emparanza et al. (2015) also established that embracing evidence-based practice
(EBP), characterized by weekly training sessions and journal clubs, led to more effective care. A
notable improvement in patient outcomes was reduced mortality rates. Following the
reconfiguration of the internal medicine unit to support EBP and the introduction of weekly
training sessions, the risk of death declined from 7.75% to 6.27%. Also, the length of stay was
shortened from 8.46 days to 6.01 days.
Another systematic evaluation of health interventions was carried out with the intention
of gathering, evaluating, and synthesizing the currently available evidence of educational
interventions on evidence-based in nursing. The educational interventions were generally similar,
and created encouraging effects in participants, giving them the skills they needed to carry out
each stage of the evidence-based in nursing, and a particular emphasis on using the evidence in
patient care (Häggman-Laitila et al., 2016).
The studies by Wu et al. (2018) and Emparanza et al. (2015) show that the in-service
training program for providers will enhance patient outcomes. The program will address the
knowledge gaps pointed out by Barter et al. (2020). The training program will enhance
uniformity in administering low-density lipoprotein cholesterol (LDL-C). The proper
administration of LDL-C will minimize adverse drug events resulting from the uncertainty over
the dose to be administered.
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VI.

Purpose/ PICO Clinical Questions/Objectives.

In the healthcare system, providing consistent and high-quality care is a major difficulty
(Khammarnia et al., 2015). Modern nursing techniques, such as integrating evidence-based
practice (EBP), are required for nurses. EBP is a revolutionary problem-solving approach to
patient care that is based on the best available and valid research and leads to better treatment,
lower costs, and professional growth for nurses and other healthcare providers (Chaghari et al.,
2017). It is an important aspect of nursing care that must be incorporated into daily practice.
Nurses are the largest group of healthcare professionals, and they play an important role
in providing care and promoting healthcare standards (Chaghari et al., 2017). As a result, they
must stay current on both practical and theoretical knowledge in their field. In-service training is
one method for keeping nurses up to date on current nursing techniques. Its goal is to keep
nurses' professional skills and occupational knowledge up to date, as well as to develop best
practices for carrying out various responsibilities and tasks. Nurses who receive in-service
training are more likely to participate actively in such programs, resulting in more effective
learning and professional growth.
“For advanced practice registered nurses (APRN), does the implementation of in-service training
programs including seminars and workshops, in comparison to no in-service training improve the
implementation of evidence-based dyslipidemia management knowledge in convenient care
clinic setting within thirty days?”
P (population): advanced practice registered nurses (APRN)
I (intervention): implementation of in-service training programs
C (comparison): no in-service training programs
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O (outcome): improved knowledge in management of dyslipidemia as per evidence-based
practice
The project's goals for quality improvement will be distinctive in bridging knowledge
gaps in the use of evidence-based guidelines in the management of dyslipidemia. The study will
also investigate the suitability of an educational program based on the empowering education
concept. This methodology takes a comprehensive approach to education. The program will have
a long-term influence on Advanced Practice Providers' knowledge acquisition and retention
when it is supplemented by follow-up interventions, consequently outstanding patient care.
VII.

Definition of terms.

Atherosclerotic cardiovascular disease (ASCVD) refers to medical conditions such as
coronary heart disease (CHD), cerebrovascular disease (CVD), peripheral artery disease (PAD),
and aortic atherosclerotic disease (ASD), which are all caused by plaque formation in arterial
walls.
Convenient Care Clinic Association is a nationwide trade association of businesses and
health-care systems that offer consumers convenient, cheap, and high-quality healthcare in retail
settings.
Dyslipidemia is described as a high amount of low-density lipoprotein cholesterol, as
well as an increase in triglycerides (TGs) and plasma cholesterol, all of which contribute to the
development of atherosclerosis. Dyslipidemia is the abnormal buildup of lipids in the blood, such
as cholesterol and fat.
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Evidence-based practice (EBP) is the reasonable, balanced, and appropriate
implementation of current research and the best available data to shape policy and practice
decisions that improve consumer outcomes.
Hypercholesterolemia is a kind of dyslipidemia characterized by high levels of
cholesterol in the blood, usually 200 mg/dL or greater.
In-service training is a type of clinical education that aims to keep employees informed
on current initiatives, technology, and therapeutic agents.
VIII.

Conceptual Underpinning and Theoretical Framework of the Project.

The scope of Advanced Practice Providers requires clinicians to implement scientific
evidence into practice (Ryder & Jacob, 2021). As demonstrated in the literature, this should be
done with a theoretical and scientific foundation to help guide the process (Ryder & Jacob,
2021). With these issues in mind, it is necessary to identify a conceptual underpinning and
theoretical framework that can be used for the proposed quality improvement project to provide
in-service training for advanced practice nurses to improve evidence-based dyslipidemia
management knowledge in a Convenient Care Clinic. For the purposes of this project, the Stetler
Model was selected as the theoretical framework. Included in this section is an overview of the
model and how it can be applied to the current project.
Overview of the Model
Scholars reviewing the Stetler Model for evidence-based practice was first introduced in
1976 and further refined in 1994 (Stetler, 2001). The model was developed to help reconcile the
gap between clinical practice and research using critical thinking and decision-making steps that
would facilitate the ability of the clinicians to make safe and effective choices regarding the
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integration of research into practice (Stetler, 2001). The model is noted in the literature to be a
clinician focused model that can be used to foster practice change (Indra, 2018). To accomplish
this goal, the Stetler Model employs five steps which are intended to guide clinicians in their
ability to apply research in practice (Stetler, 2001). These steps include preparation, validation,
comparative evaluation/decision making, implementation, and execution (Parach et al., 2018).
A closer look at what is involved in each step of the Stetler Model provides additional
insight regarding how the framework can be used to support the ability of the practitioner to
utilize research effectively and efficiently. Indra (2018) provides a more complete review of the
specific steps included in the Stetler Model noting that during preparation, efforts are made to
define the purposes of the project and to search for sources of evidence that can be used to
address the identified purpose. In the second step, validation, the specific evidence needed to
address and potentially solve the problem is identified (Indra, 2018). This is followed by
comparative evaluation and decision making in which the evidence is critiqued and is evaluated
in the context of the internal and external factors that will shape project outcomes (Indra, 2018).
During the fourth phase of the model, implementation of the evidence into practice is undertaken
and refinements when applying the research are made to ensure that the project addresses
external and internal needs to foster success. In the final stage of the model, evaluation occurs,
and an effort is made to determine not only the outcomes that resulted but also the systemic
implications of the practice change (Indra, 2018).
The Stetler Model has been used by various scholars to guide evidence-based practice
change. For instance, Parach et al. (2018) note the use of the Stetler Model to undertake a clinical
trial aimed at implementing evidence-based practice guidelines for removing arterial sheaths
following angioplasty. In this study, the authors developed the evidence-based practice
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guidelines based on the current literature and utilized the Stetler Model to guide the
implementation of the guidelines in the clinical setting. To evaluate outcomes, the authors
utilized 200 patients assigned to either care as usual or to the new treatment guidelines group.
The steps of the Stetler Model were reviewed by the authors who noted that during preparation
the problem of removing arterial sheaths was undertaken via an exhaustive literature search. In
step two of the model the guideline was developed and validated based on the literature and
expert review. During step three of the model, comparative study and decision making, the
authors note working with nurses and residents to determine if the guideline was practical for
use. This led to step four in which the refined guideline was used to train healthcare providers
and to implement the guideline in practice. The final step in the model was completed through an
evaluation of the outcomes of the trial which did indicate that the care as usual group had higher
rates of bleeding, hematoma, vasovagal reactions, urinary retention, and back pain. Based on the
results the authors recommend the use of the guideline to improve care of patients requiring the
removal of an arterial sheath following angioplasty.
While the research provided by Parach et al. (2018) facilitates a greater understanding of
how the Stetler Model can be applied in practice, it is worth noting that other scholars have
utilized the model to foster practice change. For example, Toler et al. (2018) utilized the Stetler
Model to implement a quality improvement project aimed at enhancing screening, treatment, and
referral for women experiencing postpartum anxiety. The project involved identifying evidence
to support the training of nurses, the implementation of the training in practice, and an evaluation
of outcomes for postpartum women who were provided with enhanced screening, treatment, and
referral (Toler et al., 2018). Additionally, Severine et al. (2016) employed the Stetler Model to
guide a practice change focused on the use of the STOP-Bang Questionnaire among hospitalized
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patients diagnosed with stroke to determine their risk for obstructive sleep apnea (OSA). In this
project, the Stetler Model was used to guide the process of grounding practice change for patient
assessment in the literature (Severine et al., 2016). Identification of the STOP-Bang
Questionnaire for assessing OSA risk as well as providing nurses with training and implementing
and evaluating the practice change were all included as part of operationalizing the Stetler Model
(Severine et al., 2016).
Application of the Stetler Model to the Proposed Project
By reviewing the model and its application in past evidence-based practice project
development detailed it is possible to consider how the model will be applied in the context of
the current project to implement in-service training to increase knowledge of Advanced Practice
Providers currently working in a convenient care clinic, supported by evidence-based
dyslipidemia management. Below is included a summary of each of the steps in the model and
how they will be met in the context of this project:
•

Step 1, Preparation: Preparation was completed for this project through a review of the
literature to identify the scope of the problem and potential solutions: i.e., provider
education.

•

Step 2, Validation: This step is being completed at the current time through a critique and
evaluation of the literature in the context of the organization: i.e., a convenient care
clinic. The strengths, weaknesses, opportunities, and threats analysis (SWOT) completed
in this assessment provides a foundation for evaluating the evidence and its feasibility for
application within the target organization.

•

Step 3, Comparative Evaluation/Decision Making: This step will be accomplished
through a synthesis of the evidence to develop an educational/training program for
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Advanced Practice Providers currently working at the site. A comparison of content will
be needed to determine what training should be provided to nurses.
•

Step 4, Implementation: Based on the creation of the evidence-based training module,
education will be provided to Advanced Practice Providers working at the convenient
care clinic, following Institutional Review Board (IRB) approval of the project.

•

Step 5, Evaluation: Evaluation for the project will occur through measuring knowledge
improvements made by Advanced Practice Providers through a comparison of knowledge
assessments completed before and following the educational intervention. Additionally,
an effort will be made to review the outcomes of the project in terms of their systemic
implications for patient health and maintaining the project at the site.

IX.

Methodology.

The quality improvement project will be implemented at Convenient Care Clinics in
retail pharmacies in South Florida. The clinics are committed to provide quality care to all people
despite their ethnicity, age, religion, sexual orientation, gender, and economic status. The clinics
strive to provide patient-centered care and alleviate human suffering by offering compassionate, highquality care, transforming care, and leading life-changing through providers’ education, innovative
research, and prevention. As for vision, Convenient Care Clinics are determined to meet the health

needs of their community by offering comprehensive care towards treatment of acute medical
ailments like respiratory infections, skin rashes, immunizations, etc., and management and
prevention of chronic health conditions, including hyperlipidemia, hypertension, diabetes, among
other disorders.
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Healthcare professionals specifically Advanced Practice Providers (APPs) at Convenient
Care Clinics will be contacted through email with prior authorization by the Director of Clinical
Operations and Advanced Practice Providers (APPs) Supervisor. The quality improvement
project aims to educate at least 80% of these providers. While participation in this quality
improvement program is voluntary, providers are highly encouraged to join in.
The Advanced Practice Providers (APPs) at Convenient Care Clinics will receive
educational training material in a voice over PowerPoint format about best ways to manage, treat
and prevent dyslipidemia to address the potential gap in knowledge. The participants will be
provided with a link to access the pre and post-test questionnaires to evaluate their boost in
knowledge at the end of the training.
1.

Between July and October 2022, Advanced Practice Providers (APPs) from convenient

care clinics will have online access to pre-test, educational module in a voice over PowerPoint
format, and post-test activities.
2.

Questionnaires will be developed to assess Advanced Practice Providers’ knowledge of

managing dyslipidemia and health conditions associated with this condition.
3.

Educate at least 80% of Advanced Practice Providers (APPs) at Convenient Care Clinics

by the end of the projected educational training intervention about best ways to manage, treat and
prevent dyslipidemia.
In this quality improvement project, it is unlikely for the participants to encounter any
risks that can adversely impact their social, physical, psychological, and economic health since
no experiments in humans will occur. Advanced Practice Providers (APPs) will voluntarily
participate in this project and will have the freedom to withdraw, or refuse participate at any
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phase of its execution. All Advanced Practice Providers participating in the quality improvement
project will be served with the investigators’ contact information in the participant recruitment
letter.
X.

Results

The results from this quality improvement project were tabulated utilizing descriptive and
inferential statistics. Descriptive statistics were used to tabulate the demographics of the sample
and to assess the average pre- and post-intervention knowledge scores. The demographic data is
summarized in Table 1. The results indicate that for this project a total of n = 24 participants
were included. Of these 96% (n = 23) were female, 25% (n = 6) were White, 21% (n = 5) were
African American, 46% (n = 11) were Latino, and 8% (n = 2) identified as “other” for race.
Regarding age, most of the participants, 50% (n = 12) identified as being between the ages of 40
and >50.
Table 1
Demographic Data for Participants (n = 24)
Characteristic

Result: n(%)

Gender
Female
Male

23 (96%)
1 (4%)

Race
White

6 (25%)

African American

5 (21%)

Latino

11 (46%)

Other

2 (8%)

Age
30 - 39 (Category 2)

6 (25%)
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40 - 49 (Category 3)

6 (25%)

> 50 (Category 4)

12 (50%)

Descriptive statistics were also used to tabulate the mean knowledge score before and
following the implementation of the educational module. To tabulate the mean scores, the
number of questions answered correctly on the knowledge tests was scored for each participant.
The scores were then averaged over the sample size of 24. Standard deviation was also
calculated for both the pre- and post-test knowledge scores. The averages and standard
deviations can be found in Table 2. A visual comparison of the pre- and post-test means are
provided in Figure 1.
Table 2
Pre- and Post-Intervention Knowledge Test Scores
Mean

Standard Deviation

Pre-Test Score

5.5

3.48

Post-Test Score

13.5

4.41

Figure 1
Visual Comparison of Mean Pre- and Post-Intervention Knowledge Scores
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As noted in Table 2, the pre-intervention knowledge score was 5.5 before the educational
module and increased to 13.5 following education. Figure 1 demonstrates that this is an increase
in the scores, suggesting that knowledge increased following the educational module. Even
though this does indicate an increase in knowledge scores for participants, the data presented in
Table 2 and Figure 1 does not indicate if the results were statistically significant. To assess the
statistical significance of the results, a paired t-test was used to compare the results inferentially.
Results from the paired t-test indicated the following results, t(23) = 5.33, p <.001. Using an
alpha value of 0.05, this indicates that the increase in knowledge scores that occurred following
the educational intervention was statistically significant.
XI.

Discussion

As noted, the results of this quality improvement project do indicate that there was an
increase in knowledge scores for providers. This change in scores was noted to be statistically
significant (p < .001). Provider knowledge gains made because of this quality improvement
project are not surprising given the evidence base that was reviewed to support this project. For
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example, Wändell et al. (2018) found that patient nonadherence with medical recommendations
for the treatment of dyslipidemia was related to a lack of knowledge, education, and support
provided by clinicians when treating the patient. According to Wändell and coauthors, the lack of
counseling for patients regarding their condition and its management prevent patients from
effectively engaging in their own self-care. This situation can be complicated when considering
the unique needs of patients. Alefishat et al. (2021) found that patient knowledge of lipid
lowering medications was lacking, often resulting in their lack of engagement in provider
counseling and education to help regulate dyslipidemia.
Although the current quality improvement project did not measure the impact of
education on outcomes for patients, the long-term implications of this project should be a change
in practice. A review of the literature on provider education does indicate that this intervention
can be quite helpful for strengthening care practices and clinical outcomes for patients. For
instance, Zhang et al. (2019) investigated the use of a provider education program to increase
preexposure prophylaxis prescribing among primary care providers. Outcomes measured in this
project included changes in provider knowledge following education and increased prescribing
for PrEP within the practice. The results of the study did indicate that provider education did lead
to a concomitant change in practice. Further, Loots et al. (2021) examined provider education to
help improve medication adherence in patients with severe mental illness, The results of this
systematic review and meta-analysis indicated that across 28 different studies provider education
was consistently linked with improving medication adherence in patients: p = 0.29; I2 = 19.9%.
Provider education should, therefore, have marked implications for improving outcomes for
patients, suggesting that the long-term benefits of this project will be attained because of
providing education to clinicians on the topic.
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Limitations
Although the results of this project do indicate that provider education was an effective
intervention for improving provider knowledge of dyslipidemia management, the project is not
without its limitations. The project was conducted at a same setting (Convenient Care Clinics)
and utilized a small sample of 24 Advanced Practice Providers (APPs). The sample coupled with
the selection of participants from a same setting will impact the generalizability of the findings.
This indicates that while the findings are relevant and statistically meaningful for the practice
setting where the educational program was provided, the same results may not be produced if the
intervention was implemented in a different type of practice setting. Generalizability of the
findings is needed to ensure that the project can be utilized by nurses in different healthcare
settings and communities.
An additional limitation of the project is that it did not include a designated control
group. This quality improvement project utilized a one-group study design which limits
comparison of the results. In pure experimental research a control group is often utilized to
provide a true comparison of groups to demonstrate the effect of an intervention (Khaldi, 2017).
In the current project, it is not possible to state that the educational intervention caused an
increase in knowledge. Without a separate control group in which to measure the same outcome
and provide a comparison, causality cannot be proven. While it is reasonable to state that the
change in knowledge was more than likely caused by the educational intervention because this is
not experimental research, it is not possible to state with certainty that this is the case. This may
influence the willingness of other providers and healthcare facilities to implement this type of
quality improvement.
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Limitations of the project also stem from the short duration of time to implement the
project. The project was implemented over a three-month period and the results measured only
focused on provider knowledge. If the project had been implemented over a longer time, it is
possible that the impact of the intervention on provider practice and patient outcomes could have
been measured. While it is assumed that provider education and increased provider knowledge
will lead to a change in practice—as this hypothesis has been supported in the literature—there
are no guarantees that this will occur. Consequently, while it is assumed that increases in
provider knowledge will lead to improvements in practice and better outcomes for patients, this
cannot be stated with certainty based on the results obtained from this quality improvement
project.
XII.

Implications for Advanced Practice Nursing

Dyslipidemia is a preventable condition that remains a significant public health issue in
the United States. Effective management of dyslipidemia has become a challenge because of the
knowledge gap about proper treatment practices among healthcare practitioners in the U.S. and
the entire world (Chaghari et al., 2017). Health providers’ knowledge is critical towards the
treatment of diseases. However, studies indicate that lack of adequate knowledge among health
care providers drives them to fail to implement proper mechanisms in preventing and managing
dyslipidemia. Thus, health care providers need to receive continuous education to remain
updated to modern medical practices.
An implementation of a quality improvement educational training about treatment and
management of dyslipidemia will help Advanced Practice Providers enhanced knowledge of
optimal treatment approach for their patients. At least 80% of Advanced Practice Providers
(APPs) from Convenient Care Clinics should have completed the pre- and post-data
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questionnaire to assess the success of the training and educational module by the end of the
training. The educational intervention program is expected to improve the Advanced Practice
Providers (APPs) knowledge of managing dyslipidemia, as well as the accurate prescription of
dyslipidemia drugs and the use of evidence-based treatment approaches. Healthy lifestyles, better
adherence to treatment methods among patients with dyslipidemia, and a decrease in new
instances of dyslipidemia and its associated healthcare issues are among the other results.
XIII.

Conclusions

Dyslipidemia is a treatable condition that requires expert healthcare provider knowledge
to ensure optimal outcomes for the patient. Gaps in provider knowledge regarding this topic have
resulted in the disengagement of patients in care, leading to their nonadherence with medical
advice. While nonadherence can be shaped by myriad factors, current evidence indicates that the
patient’s lack of involvement in their care is, to some extent, impacted by a lack of healthcare
provider knowledge on the topic. Provider education was demonstrated in this project to be
highly effective for increasing provider knowledge of proper dyslipidemia management. The
results, when reviewed in the context of the literature, do suggest that provider education should
result in a change in provider behavior. This should, over the long-term, result in the application
of evidence-based practice to patient care leading to better outcomes for patient and population
health.
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Appendix B: Support Letter from UHealth.
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Appendix C: Recruitment letter for “Bridging the Knowledge Gap in the Management of
Dyslipidemia: A Quality Improvement Project”.
Dear UHealth Clinic APRN Provider:
My name is Annery Diaz, and I am a Doctor of Nursing Practice (DNP) student from the
Nicole Wertheim College of Nursing and Health Science, Graduate Department at Florida
International University. The purpose of this letter is to invite you to participate in a Quality
Improvement project that will be conducted to fulfill the requirements to obtain the Doctor in
Nursing Practice (DNP) degree at Florida International University (FIU). In this project, how
providers manage dyslipidemia will be assessed.
If you agree to participate, you will be asked to answer some questions about how you
manage dyslipidemia in your patients. This will be done following a link that will be submitted
by our Director of Clinical Operations. The process will have a pre-test, followed by an
educational activity (voice-over PowerPoint presentation), and concluded with a post-test
questionnaire. Each activity will take approximately 20-30 minutes of your time, in a 30-day
period. Investigator will be the only individual collecting and analyzing the information, and no
identifiable private information will be gathered. All information will be anonymous and
handled electronically in a computer protected with a password. No hard copies.
Your participation is voluntary. If you decide to participate in this project, there is no
risks associates with it. The potential benefits that participants may expect because of this project
include more knowledge related to manage dyslipidemia and being in a better position to treat
patients with this medical condition. Participation in this activity will not interfere with the
normal function of our clinics, nor will it involve access to patients’ medical records.
I want to thank you in advance for your time and desire to participate and support this
academic activity. If you have any questions about the project, please feel free to contact me at
adiaz013@fiu.edu, axd1226@miami.edu, or (786) 514-0483.
Thank you very much, sincerely

Annery Diaz
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Appendix D: Educational Module: Pre- and Post-Test
1.

Atherosclerotic cardiovascular disease (ASCVD) accounts for approximately what
percentage of deaths in the United States?

A.

10%

B.

26%

C.

31%

D.

55%

2.

Approximately what percentage of Americans 20 years of age or older have total blood
cholesterol levels in excess of 240 mg/dL?

A.

5%

B.

8%

C.

12%

D.

15%

3.

Which of these statements regarding atherosclerosis is TRUE?

A.

Atherosclerosis is initiated during middle-age.

B.

Atherosclerosis is a process that targets small sized arteries.
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C.

Atherosclerosis is rapidly accelerated by genetic and environmental factors.

D.

All of the above

4.

All of the following are progressive stages of atherosclerosis, EXCEPT:

A.

plaque formation.

B.

plaque disruption.

C.

fatty streak formation.

D.

high-density lipoprotein.

5.

Which of the following is NOT considered a biomarker for ASCVD?

A.

Age

B.

Lipoprotein(a)

C.

C-reactive protein

D.

Hyperhomocysteinemia

6.

Increased LDL levels can result from:

A.

a deficiency of estrogens.

B.

a deficiency of thyroid hormones.

C.

genetic mutations of either the LDL receptor or Apo B-100.

D.

All of the above

7.

With an incidence greater than 25% in the United States, the most common form of
secondary hyperlipidemia is:
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A.

atherogenic dyslipidemia.

B.

familial hypertriglyceridemia.

C.

familial hypercholesterolemia.

D.

polygenic hypercholesterolemia (or nonfamilial hypercholesterolemia).

8.

Secondary hyperlipidemias can be precipitated by the use of certain medication
treatments. These treatments include estrogen therapy, atypical antipsychotics,
corticosteroids, and

A.

statins.

B.

fibrates.

C.

thiazides.

D.

antioxidants.

9.

The primary goal of lipid therapy in high-risk patients is to reduce LDL cholesterol by

A.

10%.

B.

25%.

C.

40%.

D.

50% or more.

10.

The 2018 AHA/ACC guideline recommendations for a heart-healthy dietary pattern
include all of the following, EXCEPT:

A.

Low-fat dairy products
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B.

Increased calories from trans fats

C.

Fruits, vegetables, and whole grains

D.

No more than 5% to 6% of calories from saturated fats

11.

Which of the following statements regarding lipid management through lifestyle change
is TRUE?

A.

Lipid lowering goals can usually be achieved on one’s own.

B.

Lipid lowering through diet and exercise will not reduce the risk for ASCVD and
mortality.

C.

Successful lipid control usually requires instruction by a dietitian or other knowledgeable
healthcare professional.

D.

In patients with high cardiovascular risk and/or very high LDL, medication therapy
should be initiated if lifestyle changes are not effective within a two- to three- month
period.

12.

In addition to lowering lipid levels, statins are thought to have all of the following
pleiotropic effects, EXCEPT:

A.

neuroprotection.

B.

modulation of endothelial function.

C.

an increase in vascular inflammation.

D.

immunomodulation by inhibition of major histocompatibility complex II expression.
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13.

Research has shown that moderate-to-high HDL levels may help to prevent ASCVD. The
main goal for patients with hyperlipidemias should be to

A.

increase HDL levels.

B.

decrease LDL levels.

C.

increase triglyceride levels.

D.

All of the above

14.

Niacin, or nicotinic acid, is also known as what vitamin?

A.

Vitamin B3

B.

Vitamin D2

C.

Vitamin E2

D.

Vitamin B12

15.

Omega-3 fatty acids are abundant in what dietary sources?

A.

Walnuts

B.

Fatty fish

C.

Canola oil

D.

All of the above
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Appendix E: Literature Matrix
First
Author/Year

Ab et al.
(2009)

Alefishat et al.
(2021)

Barter et al.
(2020)

Purpose/
Problem/
Objective/
Aims

Study Design

Sample
(Setting)

To find out
why healthcare
practitioners
don't provide
lipid-lowering
treatment to
patients with
type 2 diabetesmellitus.

A qualitative
study was
conducted using
semi-structured
interviews to
explore the
reasons for not
prescribing
lipid-lowering
drugs. The
results were
analyzed using
an inductive
analytic
approach.
In this crosssectional study,
patients having
a diagnosis of
dyslipidemia for
six months or
longer and a
prescription for
at least one
medicine to
control blood
lipids were
recruited and a
four-item
medication
adherence
measure
(questionnaire)
was used.

Seven
general
practitioners
working in
the
Netherlands.

Individual
semistructured
interviews
that were
transcribed
and coded.

A total of
228 patients
with
dyslipidemia
who were
being seen in
a primary
care practice
in Jordan.

Data
collection
occurred
through the
Beliefs about
Medicines
Questionnaire
which was
used to assess
patients’
beliefs about
medications

This study used
an online
questionnaire
and conducted a
web-based
survey
involving
physicians from
the Philippines,
Colombia,
Germany, and
Japan.

Web-based
survey of
1758
physicians in
Japan,
Germany,
Colombia,
and the
Philippines
selected from
specific
databases.

Data
collection
occurred
through a
web-based
survey of
physicians.
The survey
covered
dyslipidemia
management,
target lowdensity
lipoprotein
cholesterol
(LDL-C)
levels in
different
patient

To assess
medication
adherence in
patients with
dyslipidemia
and investigate
the reasons that
lead to nonadherence.

To obtain a
better
understanding
of physician
views and
behavior, and
to identify
uncertainty in
dyslipidemia
management
across the
Philippines,
Colombia,
Germany, and
Japan.

Data
Collection
Measures

Results

Strengths/
Limitations

Relationship
to Project

Level of
Evidence/
Quality
Ranking

The study
revealed
patients and
providers
barriers in not
prescribing
lipid lowering
medications.
Treatment
quality could
improve if
motivation and
lack of
knowledge are
addressed.
Most of the
patients said
they didn't take
medications as
prescribed.
Modifiable
factors
associated to
poor adherence
were views
about
perceived risk,
drug hazards,
treatment
length, and
medication
number.
Simplifying
prescription
regimen by
lowering the
number of
medications
may enhance
medication
adherence and
health-related
outcomes.
The study
gives a picture
of the views
and behaviors
of physicians’
participants
who manage
dyslipidemia
patients in their
daily practice.
The findings
point to crucial
areas where
more teaching
and
investigation
are needed.

Strengths: Results
highlight provider
obstacles and provide
in-depth analysis.

This article
demonstrates
the barriers
faced by
providers in
addressing
high lipid
levels. This is
foundational to
the problem
being
investigated in
this quality
improvement
project.
This study
demonstrates
the need for the
current project,
highlighting
the fact that
patients face
notable barriers
when it comes
to medication
adherence,
which can
make it
difficult for
providers to
effectively
improve
patient lipid
levels.

Level III
Quality B

Weaknesses: No
quantitative data,
small sample size,
inability to generalize
the results.

Strengths:
Quantitative data
which highlights the
problem, statistically
significant results.
Weaknesses: Nonexperimental study,
small sample size, no
comparison/causality,
lack of
generalizability.

Strengths: Results
are robust and
demonstrate gaps in
provider knowledge,
quantifiable results,
international sample.
Weaknesses: Use of
a non-experimental
framework, small
sample size, no
comparison/causality,
lack of
generalizability.

This study
demonstrates
that providers
have definitive
and similar
deficiencies in
knowledge
regarding the
treatment of
dyslipidemia,
which is the
problem noted
for the project.

Level III
Quality A

Level III
Quality A
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Chaghari et al.
(2017)

Chen et at
(2020)

Emparanza et
al. (2015)

Germossa et
al. (2018)

To develop a
new ideal inservice training
model and
improve the
efficacy of this
form of
education for
nurse
personnel.

To find if
statins, fibrates,
nicotinic acid,
and ezetimibe,
among other
lipid-lowering
drugs, lowered
the risk of
recurrent stroke
in ischemic
stroke patients,
and if these
findings could
help guide
treatment
decisions for
blood lipidlowering drugs.

To decide if
EBP improves
patient
outcomes when
compared to
those who get
standard
medical care
(SP).

To find out
how an inservice
educational
program affects
nurses'
knowledge and
attitudes about
pain
management.

groups, and
statin safety.
Data were
collected
through
interview,
observation,
and field
notes. Data
was analyzed
through
MAXQDA10.

A qualitative
study was
undertaken
using Grounded
Theory to
investigate the
process of
training nurses
and theory
formation to
develop the best
model for inservice nursing
staff training.
In a metaanalysis, the
relative risk of
stroke
recurrence in
groups of
patients treated
with either
blood lipidlowering
regimens or
placebo was
calculated using
a fixed effects
model and
linear and spline
regression.

The sample
included 35
nurses.

The sample
included five
studies that
involved
4,999
patients.

Data were
collected
through
PubMed,
EMBASE,
Cochrane
Library and
Chinese
databases
CNKI, SinoMed, Wan
Fang, and
VIP. A
PRISMA
flow diagram
was used
along with a
metaanalysis.

This crosssectional study
sought to
explore nursing
students’ beliefs
and
implementations
of EBP, to
examine the
differences in
students’ beliefs
and
implementations
by prior training
of EBP, and to
examine the
relationship
between the
same.
A quasiexperimental
investigation
was carried out.
Two days of
rigorous pain
management
education were
offered,
followed by a
one-month
follow-up
training session.
The impact of

A sample of
241 nursing
students from
two public
universities.

A survey that
contained
questions
regarding
learning and
teaching
regarding
evidencebased
practice.

A total of
111 nurses
working
Jimma
University
Medical
Center at

The
Knowledge
and Attitudes
Survey
Regarding
Pain
(KASRP)
was used for
data
collection.

A new model
for in-service
nurse training,
empowering
education, can
help nurses
perform their
jobs more
effectively and
master their
professional
abilities.

Strengths: Results
highlight provider
obstacles and provide
in-depth analysis.

The incidence
of ischemic
stroke
recurrence was
considerably
reduced when
low-density
lipoprotein
cholesterol
(LDL-C) was
reduced by
50% or more.
The overall
positive benefit
of statin
medication in
preventing
ischemic stroke
recurrence has
been
demonstrated.
Nurses’ beliefs
regarding EBP
influenced
their
implementation
of it. Nurse had
a low belief
score and a
much lower
implementation
score,
suggesting that
there are
challenges in
both areas.

Strengths: High
level of evidence,
statistically
significant results.

Nurses'
knowledge and
attitudes about
pain
management
increased
because of the
teaching
program.
Nurses may be
able to control
pain more
effectively
because of this.

Strengths:
Experimental study,
statistically
significant results.

Weaknesses: No
quantitative data,
small sample size,
inability to generalize
the results.

Weaknesses:
Limited number of
databases used for
searching, results
may be limited.

Strengths:
Quantitative data
demonstrating the
need for education to
implement EBP,
robust and relevant
results.
Weaknesses: Small
sample, lack of
generalizability, no
comparison,
nonexperimental
approach.

Weaknesses: Small
sample, no
comparison group,
lack of
generalizability.

Article
demonstrates
the utility of
training to
improve nurse
knowledge.
This is the
specific focus
of the current
quality
improvement
project.

Level III
Quality A

Article
demonstrates
the benefits of
statins and
indicates that
providers need
to be educated
to provide this
treatment for
patients to help
prevent
adverse
outcomes
(stroke).

Level I
Quality A

Article
highlights the
importance of
education to
improve the
implementation
of evidencebased practice.
This is the
focus of the
quality
improvement
project focused
on
dyslipidemia.

Level III
Quality A

The article
demonstrates
the positive
effect of nurse
education. This
quality
improvement
project is
investigating
nurse
education to
improve
patient
outcomes. This

Level II
Quality A
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HäggmanLaitila et al.
(2016)

Wändell et al
(2018)

To collect,
evaluate, and
synthesize
current
evidence
regarding
educational
interventions in
evidence-based
nursing (EBN).

To determine
possible
facilitators and
barriers for
health care
workers to
engage in
selective
cardiometabolic
disease (CMD)
prevention in
primary care.

educational
programs was
measured using
a tool.
The study is a
systematic
review based on
the Centre for
Reviews and
Disseminations'
protocol for
performing
health
intervention
reviews.
Narrative
synthesis was
used to analyze
the data, as well
as qualitative
content analysis.
The current
study is a
systematic
search and
review of
literature in
primary health
care with
relevant
material on
targeted
prevention of
cardiometabolic
disorders
(CMD).

article supports
the project.

Study
included 13
studies
reviewing 13
different
educational
interventions.

A total of 19
studies
including 7
quantitative
studies, 2
mixed
methods
studies, and
10 qualitative
studies.

Data
collected
through
evaluation of
Cochrane,
CINAHL and
PubMed
MEDLINE
databases
from January,
1, 2008
through
February 26,
2015.
Organized
using a
PRISMA
Diagram.
Articles
selected from
Medline,
Embase,
CINAHL and
PubMed and
organized
using a
PRISMA
diagram.

Learners were
prompted to
critically assess
and evaluate
their practice
because of the
interventions.
Participants'
ability to
recognize the
need for
research
evidence in
clinical
practice was
also improved.

Strengths: High
level of evidence,
statistically
significant results.

Both
qualitative and
quantitative
research
highlighted
structural,
organizational,
professional,
social
environment,
and attitudinal
challenges and
facilitators of
selective CMD
preventive
initiatives in
primary care.

Strengths: High
level of evidence,
statistically
significant results.

Weaknesses:
Limited number of
databases used for
searching, results
may be limited.

Weaknesses:
Limited number of
databases used for
searching, results
may be limited.

This high level
of evidence
demonstrates
that the
intervention
selected for
this quality
improvement
project is
effective. This
evidence
justifies the
selected
intervention.

Quality I
Level A

This systematic
review
demonstrates
the importance
of managing
dyslipidemia.
This supports
the problem of
lack of
provider
knowledge to
effectively
manage this
condition.

Level I
Quality B

